Beta-endorphin disregulation in autistic and self-injurious behavior: a neurodevelopmental hypothesis.
Peptides derived from pro-opiomelanocortin (POMC) influence neurodevelopmental processes. Earlier studies indicated that MSH/ACTH compounds improved behavioral efficiency in retarded individuals. Recent studies have shown that opiate blockers reduce treatment-resistant self-injurious behavior (SIB), an autistic-like, developmental disorder. Although the exact mechanisms are unknown, prenatal POMC disregulation, addiction to endogenous opiates and elevated pain threshold have been proposed to account for this behavior. In study one, four SIB patients were given 0, 25, 50 or 100 mg of naltrexone on separate weeks in a double blind, Latin square design. A specific dose dependent reduction in SIB was observed in three patients. In study two, plasma b-endorphin was measured in 40 patients with SIB, a related behavior, stereotypy (ST) or controls. SIB and ST patients had higher levels of endorphin than controls. These data added new support for the role of b-endorphin in a treatment-resistant patient group.
Sandman
C A
CA
State Developmental Research Institute, Fairview, Costa Mesa, California 92626.
D000328:Adult; D001321:Autistic Disorder / Q000188:drug therapy / Q000503:physiopathology*; D002986:Clinical Trials as Topic; D002658:Developmental Disabilities / Q000188:drug therapy / Q000503:physiopathology*; D006706:Homeostasis; D006801:Humans; D008297:Male; D009270:Naloxone / Q000627:therapeutic use*; D009271:Naltrexone; D001615:beta-Endorphin / Q000097:blood / Q000502:physiology*
D009270:Naloxone; D009271:Naltrexone; D001615:beta-Endorphin